title: Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
abstract: The time course of the concentration of active thrombin in clotting plasma (the thrombogram) was measured by subsampling from platelet-rich plasma (PRP) and continuous chromogenic measurement of platelet-poor plasma (PPP) in 41 stroke patients under the age of 50, in whom stroke could not be attributed to cardioembolic disease, arterial dissection or vasculitis. A significant increase in the area under the thrombogram (endogenous thrombin potential, ETP) was seen in 23 patients. In 9 of them, ETP was increased in PRP but normal in PPP. High ETP in PRP was significantly associated with stroke, both in the middle and in the highest tercile of the ETP (odds ratio 5.1, range 1.8-15.1, and 3.7, range 1.3-10.3, respectively). A decreased sensitivity to the inhibitory action of thrombomodulin (TM) on thrombin generation was observed in 5 of 37 cases. No further definition of the cause of increased thrombin generation or TM resistance was attempted, except for the role of von Willebrand factor (vWF). ETP in PRP, platelet-derived procoagulant activity and vWF were correlated and higher in patients than in controls (p=0.002, p=0.045 and p=0.0006, respectively). This confirms the correlation between vWF level and stroke at young age found in epidemiological studies. It suggests that the role of vWF in thrombin generation, which has been demonstrated in vitro, may be the underlying mechanism of this correlation. In summary, hypercoagulability, defined as an increased capacity of the platelet plasma system to form thrombin, is found in over half of the patients under 50 years with an otherwise unexplained stroke. Sometimes it is due to increased plasma factor activity, sometimes to an increased procoagulant activity of the platelets.
authors.affiliation: Department of Neurology, University Hospital Maastricht, Maastricht, The Netherlands. cta@sncu.azm.nl
authors.forename: C G
authors.initials: CG
authors.lastname: Faber
authors.forename: J
authors.initials: J
authors.lastname: Lodder
authors.forename: F
authors.initials: F
authors.lastname: Kessels
authors.forename: J
authors.initials: J
authors.lastname: Troost
mesh_terms: D000328:Adult; D017668:Age of Onset; D019540:Area Under Curve; D001780:Blood Coagulation Tests / Q000379:methods; D002545:Brain Ischemia / Q000097:blood* / Q000453:epidemiology / Q000209:etiology; D002863:Chromogenic Compounds; D015897:Comorbidity; D006801:Humans; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D010949:Plasma; D010976:Platelet Count; D012008:Recurrence; D012680:Sensitivity and Specificity; D013917:Thrombin / Q000032:analysis / Q000096:biosynthesis*; D018180:Thrombomodulin / Q000737:chemistry; D019851:Thrombophilia / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D014841:von Willebrand Factor / Q000032:analysis / Q000502:physiology
chemical_list: D002863:Chromogenic Compounds; D010743:Phospholipids; D018180:Thrombomodulin; D014841:von Willebrand Factor; D013917:Thrombin